Connor, Clark & Lunn Investment Management (CC&L)’s Corvus Pharmaceuticals CRVS Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-137,031
| Closed | -$724K | – | 1437 |
|
|
2024
Q3 | $724K | Buy |
137,031
+53,809
| +65% | +$284K | ﹤0.01% | 981 |
|
|
2024
Q2 | $151K | Sell |
83,222
-4,786
| -5% | -$8.71K | ﹤0.01% | 1285 |
|
|
2024
Q1 | $157K | Buy |
88,008
+16,800
| +24% | +$29.9K | ﹤0.01% | 1426 |
|
|
2023
Q4 | $125K | Buy |
71,208
+325
| +0.5% | +$572 | ﹤0.01% | 1303 |
|
|
2023
Q3 | $103K | Sell |
70,883
-13,485
| -16% | -$19.7K | ﹤0.01% | 1289 |
|
|
2023
Q2 | $193K | Buy |
+84,368
| New | +$193K | ﹤0.01% | 1194 |
|
|
2020
Q3 | – | Sell |
-84,918
| Closed | -$231K | – | 957 |
|
|
2020
Q2 | $231K | Sell |
84,918
-686
| -0.8% | -$1.87K | ﹤0.01% | 879 |
|
|
2020
Q1 | $181K | Buy |
85,604
+3,804
| +5% | +$8.04K | ﹤0.01% | 878 |
|
|
2019
Q4 | $445K | Buy |
81,800
+7,075
| +9% | +$38.5K | ﹤0.01% | 682 |
|
|
2019
Q3 | $225K | Buy |
74,725
+10,400
| +16% | +$31.3K | ﹤0.01% | 841 |
|
|
2019
Q2 | $241K | Buy |
64,325
+5,374
| +9% | +$20.1K | ﹤0.01% | 867 |
|
|
2019
Q1 | $237K | Buy |
58,951
+9,101
| +18% | +$36.6K | ﹤0.01% | 794 |
|
|
2018
Q4 | $183K | Buy |
49,850
+1,600
| +3% | +$5.87K | ﹤0.01% | 860 |
|
|
2018
Q3 | $414K | Buy |
48,250
+650
| +1% | +$5.58K | ﹤0.01% | 734 |
|
|
2018
Q2 | $523K | Buy |
47,600
+2,900
| +6% | +$31.9K | ﹤0.01% | 757 |
|
|
2018
Q1 | $515K | Buy |
44,700
+12,900
| +41% | +$149K | ﹤0.01% | 565 |
|
|
2017
Q4 | $329K | Buy |
31,800
+4,700
| +17% | +$48.6K | ﹤0.01% | 671 |
|
|
2017
Q3 | $432K | Buy |
27,100
+4,700
| +21% | +$74.9K | ﹤0.01% | 656 |
|
|
2017
Q2 | $271K | Buy |
+22,400
| New | +$271K | ﹤0.01% | 692 |
|